QC
KNSA icon

Quadrature Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Quadrature Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,440
Closed -$289K – 1280
2025
Q2 		$289K Buy
+10,440
New +$266K 0.01% 697

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrature Capital's KNSA Position: Q3 2025 in Review

Quadrature Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 10,440 shares — an estimated $289K sold.

Quadrature Capital first reported a position in KNSA in Q2 2025 and held it in 1 quarter. The position peaked at $289K in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Quadrature Capital reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 10,440 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $289K.
  • Quadrature Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Quadrature Capital's Kiniksa Pharmaceuticals position peaked at $289K in Q2 2025.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.